Optical Imaging of Beta-Amyloid Plaques in Alzheimer's Disease

Biosensors (Basel). 2021 Jul 29;11(8):255. doi: 10.3390/bios11080255.

Abstract

Alzheimer's disease (AD) is a multifactorial, irreversible, and incurable neurodegenerative disease. The main pathological feature of AD is the deposition of misfolded β-amyloid protein (Aβ) plaques in the brain. The abnormal accumulation of Aβ plaques leads to the loss of some neuron functions, further causing the neuron entanglement and the corresponding functional damage, which has a great impact on memory and cognitive functions. Hence, studying the accumulation mechanism of Aβ in the brain and its effect on other tissues is of great significance for the early diagnosis of AD. The current clinical studies of Aβ accumulation mainly rely on medical imaging techniques, which have some deficiencies in sensitivity and specificity. Optical imaging has recently become a research hotspot in the medical field and clinical applications, manifesting noninvasiveness, high sensitivity, absence of ionizing radiation, high contrast, and spatial resolution. Moreover, it is now emerging as a promising tool for the diagnosis and study of Aβ buildup. This review focuses on the application of the optical imaging technique for the determination of Aβ plaques in AD research. In addition, recent advances and key operational applications are discussed.

Keywords: Alzheimer’s disease (AD); fluorescence microscopy; nonlinear optical imaging; optical imaging; β-amyloid protein (Aβ).

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / diagnostic imaging
  • Amyloid beta-Peptides*
  • Humans
  • Neurodegenerative Diseases*
  • Optical Imaging
  • Plaque, Amyloid / diagnostic imaging

Substances

  • Amyloid beta-Peptides